Currently, only one study has been conducted on the safety of semaglutide in breastfeeding
Unlike earlier GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) that target a single hormone pathway, or tirzepatide (Mounjaro/Zepbound) that targets two, retatrutide activates three distinct metabolic receptors : GIP, GLP-1, and glucagon
While most adults who have taken GLP-1 drugs say their insurance covered at least a part of the cost of these drugs, about a quarter (27%) of users with health insurance say they paid the full cost of the drugs themselves
Industry analysts project retatrutide will launch in the $1,200$1,500 monthly range , slightly above current Mounjaro/Zepbound pricing
If carbohydrates are unavailable or in short supply, the body knows it must start using up its fat stores
When evaluating patient well-being, physicians are increasingly reviewing metabolic health as an indicator of future health risk